Promising effect of infliximab on the extent of involvement in ulcerative colitis

Journal of Research in Medical Sciences

Volumn 16, Issue 1, 2011, Pages 6-15

  Adibi, Peyman ^a   Mollakhalili, Pejman ^a   Fallah, Zahra ^b   Daryani, Nasser Ebrahimi ^c   Ajdarkosh, Hossein ^d   Khedmat, Hossein ^e   Derakhshan, Faramarz ^f   Karbassi, Ashraf ^e   Ashkzari, Mahshid ^g   Tavakkoli, Hamid ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g Tehran Office   (Iran)

Author keywords

Colitis; Colon; Infliximab; Ulcerative

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; PREDNISOLONE; STEROID;

ADULT; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; HYPOTENSION; IRAN; LEUKOPENIA; MALE; MULTICENTER STUDY; OPEN STUDY; PROSPECTIVE STUDY; ULCERATIVE COLITIS;

EID: 79551700875     PISSN: 17351995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Grover P, Kamat D. Management of inflammatory bowel disease. Clin Pediatr 2007;46(4):359-64.
2. Karlinger K, Györke T, Makö E, Mester A, Tarján Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000;35(3):154-67.
3. Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB. A Review of infliximab use in ulcerative colitis. Clin Ther 2008;30(2):223-30.
4. Aberra FN, Lichtenstein GR. Infliximab in ulcerative colitis. Gastroenterol Clin North Am 2006;35(4):821-36.
5. Langan RC, Gotsch PB, Krafczyk MA, Skillinge DD. Ulcerative colitis: diagnosis and treatment. Am Fam Physician 2007;76(9):1323-30.
6. Tamboli CP. Current medical therapy for chronic inflammatory bowel diseases. Surg Clin North Am 2007;87(3):697-725.
7. Lees CW, Heys D, Ho GT, Noble CL, Shand AG, Mowat C, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007;26(3):411-9.
8. Chakravarty BJ. Predictors and the rate of medical treatment failure in ulcerative colitis. Am J Gastroenterol 1993;88(6):852-5.
9. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330(26):1841-5.
10. Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting outcome in severe ulcerative colitis. Gut 1996;38(6):905-10.
11. Lindgren SC, Flood LM, Kilander AF, Löfberg R, Persson TB, Sjödahl RI. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998;10(10):831-5.
12. Carbonnel F, Gargouri D, Lémann M, Beaugerie L, Cattan S, Cosnes J, et al. Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther 2000;14(3):273-9.
13. Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004;19(10):1079-87.
14. Mir-Madjlessi SH, Forouzandeh B, Ghadimi R. Ulcerative colitis in Iran: a review of 112 cases. Am J Gastroenterol 1985;80(11):862-6.
15. Malekzadeh R, Varshosaz J, Merat S, Hadidchi S, Mirmajlesi SH, Vahedi H, et al. Crohn's disease: a review of 140 cases from Iran. Iran J Med Sci 2000;25(3-4):138-43.
16. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol 2005;20(11):1691-5.
17. Vahedi H, Merat S, Momtahen S, Olfati G, Kazzazi AS, Tabrizian T, et al. Epidemiologic characteristics of 500 patients with inflammatory bowel disease in Iran studied from 2004 through 2007. Arch Iran Med 2009;12(5):454-60.
18. Tamizifar B, Lankarani KB, Naeimi S, Rismankar Zadeh M, Taghavi A, Ghaderi A. Promoter polymorphism of transforming growth factor-beta1gene and ulcerative colitis. World J Gastroenterol 2008;14(2):243-7.
19. Derakhshan F, Naderi N, Farnood A, Firouzi F, Habibi M, Rezvany MR, et al. Frequency of three common mutations of CARD15/NOD2 gene in Iranian IBD patients. Indian J Gastroenterol 2008;27(1):8-11.
20. Naderi N, Farnood A, Habibi M, Derakhshan F, Balaii H, Motahari Z, et al. Association of vitamin D receptor gene polymorphisms in Iranian patients with inflammatory bowel disease. J Gastroenterol Hepatol 2008;23(12):1816-22.
21. Froutan H, Nikbin B, Habibabadi M. HLA typing of ulcerative colitis in Iran. Acta Media Iranica 1996;34(1-2):52-4.
22. Daryani NE, Bashashati M, Aram S, Hashtroudi AA, Shakiba M, Sayyah A, et al. Pattern of relapses in Iranian patients with ulcerative colitis. A prospective study. J Gastrointestin Liver Dis 2006;15(4):355-8.
23. Ansari R, Attari F, Razjouyan H, Etemadi A, Amjadi H, Merat S, et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol 2008;20(1):46-50.
24. Zali M, Bahari A, Firouzi F, Daryani NE, Aghazadeh R, Emam MM, et al. Bone mineral density in Iranian patients with inflammatory bowel disease. Int J Colorectal Dis 2006;21(8):758-66.
25. Infliximab. Available at: http://www.modernmedicine.com/modernmedicine/FDA+Approvals/Infliximab/ArticleStandard/Article/detail/393075. Accessed December 1, 2006.
26. Gavalas E, Kountouras J, Stergiopoulos C, Zavos C, Gisakis D, Nikolaidis N, et al. Efficacy and safety of infliximab in steroid-dependent ulcerative colitispatients. Hepatogastroenterology 2007;54(76):1074-9.
27. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317(26):1625-9.
28. Stange EF, Travis SPL, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. Journal of Crohn's and Colitis 2008;2(1):1-23.
29. Graham L. AGA reviews the use of corticosteroids, immunomodulators, and infliximab in IBD. Am Fam Physician 2007;75(3):410-6.
30. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006;3:CD005112.
31. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353(23):2462-76.
32. Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97(10):2577-84.
33. Gornet JM, Couve S, Hassani Z, Delchier JC, Marteau P, Cosnes J, et al. Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study. Aliment Pharmacol Ther 2003;18(2):175-81.
34. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96(8):2373-81.
35. Chey WY. Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis 2001;7(Suppl 1):S30-3.
36. Kaser A, Mairinger T, Vogel W, Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 2001;113(23-24):930-3.
37. Actis GC, Bruno M, Pinna-Pintor M, Rossini FP, Rizzetto M. Infliximab for treatment of steroid-refractory ulcerative colitis. Dig Liver Dis 2002;34(9):631-4.
38. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002;34(9):626-30.
39. Bermejo F, López-Sanroman A, Hinojosa J, Castro L, Jurado C, Gómez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev Esp Enferm Dig 2004;96(2):94-101. (English, Spanish)
40. Sands BE, Tremaine WJ, Sandborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7(2):83-8.
41. Ochsenkuhn T, Sackmann M, Goeke B. Infliximab for acute severe ulcerative colitis: a randomised pilot study in non steroid refractory patients. Gastroenterology 2003;124(4 Suppl 1):A62.